- Details
- Josh Lang joins Alicia Morgans in a discussion on the importance of understanding mechanisms of resistance to targeted therapies through the development of novel liquid biopsies of the human tumor microenvironment. Lang highlights his research which looks beyond tissue biopsy to liquid biopsies of cancer cells from a blood draw to inform decision-making. Research funded by the Prostate Cancer Foun...
|
- Details
- Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
|
- Details
- Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...
|
- Details
- Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...
|
- Details
- Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...
|
- Details
- Phil Kantoff, CEO of Convergent Therapeutics, sits down with Alicia Morgans to discuss the future of radioligand therapy in the treatment of advanced prostate cancer. Philip Kantoff provides an overview of exciting results seen in studies on actinium-225, a powerful alpha-emitter tested in patients with advanced prostate cancer that also may be promising for patients with earlier-stage disease. Bi...
|
- Details
- Alicia Morgans and Matthew Smith join Charles Ryan to discuss cancer survivorship. Drs Morgans and Smith explain the holistic role that a cancer survivorship program plays in the health and well-being of prostate cancer patients, including bone health, mental health, monitoring cardiovascular risk, and more. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, A...
|
- Details
- Veda Giri joins Charles Ryan in a discussion on the EXPAND Network, EX tending P rostate Cancer Genetic A wareness, N avigation, and D elivery for genetic testing, and genetic awareness in males of African descent for Black men. This project is supported by the 2021 PCF-Pfizer Health Equity Challenge Award grant mechanism. Dr. Giri provides the rationale for this project stemming from statistics f...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans to discuss the immune checkpoint B7-H3 and its implications for prostate cancer treatment. Dr. Antonarakis provides an overview of clinical trials that tested B7-H3 and the encouraging findings of those trials. He also details some of the toxicities noted during the trials and plans for future studies given the measurable disease responses and PSA response...
|
- Details
- Channing Paller joins Alicia Morgans at ASCO 2022 to discuss considerations in the timing and intensity of ADT in biochemical recurrence. Dr. Paller gives an overview of her presentation and the two explore important considerations when timing treatment for prostate cancer after recurrence and relevant clinical trial data, such as TOAD and CRUK. In addition, they acknowledge the importance of pati...
|
